Current Weather
The Spy FM

FDA Approves Second Diet Drug In A Month

Filed by KOSU News in Health.
July 18, 2012

After a 13-year hiatus, the Food and Drug Administration gave its OK to the second weight-loss drug in a month.

This time it’s Qsymia, previously called Qnexa, from Vivus. The pill contains two active ingredients: topiramate, an anti-seizure medicine, and phentermine, a stimulant.

The two medicines, both generic now, have been around for years. By combining relatively low doses in a single pill, Qsymia helps suppress appetite and gives people a feeling of fullness more quickly after eating.

Qsymia, (say CUE-sim-ee-ah) is approved for treating obese adults (a body mass index over 30) or those who are overweight and have one weight-related condition, such as diabetes, high blood pressure or high cholesterol.

In studies leading up to approval, patients lost an average of about 8 percent of their original body weight in a year. Earlier research suggests a 5 percent weight loss can provide a benefit health.

The once-a-day pill (taken in the morning to minimize insomnia) has side effects, including mood disturbances, fuzzy thinking and an increase in heart rate. People with glaucoma shouldn’t take the drug.

The topiramate in Qsymia can cause birth defects, and the drug isn’t for use by women who are pregnant. Women of child-bearing age who take the drug will have to use effective contraception.

Because of the drug’s risk during pregnancy, Qsymia will only be available from approved mail-order pharmacies.

Peter Tam, president of Vivus, told USA Today that the drug will be available to by the fourth quarter. A price wasn’t released, but Tam told the paper it will not be “outrageous.” Insurance companies probably won’t cover the cost of the drug at first.

The FDA’s approval of Qsymia was expected, and the biggest excitement Tuesday came when USA Today published an online story prematurely. After taking the story down, the paper posted this explanation, according to the blog Retraction Watch:

USA TODAY inadvertently published a story online this morning saying the Food and Drug Administration had given approval to the diet drug Qsymia (kyoo sim ee’ uh). The story was prepared in anticipation of FDA approval, but at this hour that approval is still pending.

[Copyright 2012 National Public Radio]

Leave a Reply

5AM to 9AM Morning Edition

Morning Edition

For more than two decades, NPR's Morning Edition has prepared listeners for the day ahead with two hours of up-to-the-minute news, background analysis, commentary, and coverage of arts and sports.

Listen Live Now!

9AM to 10AM The Takeaway

The Takeaway

A fresh alternative in morning news, "The Takeaway" provides a breadth and depth of world, national and regional news coverage that is unprecedented in public media.

View the program guide!

10AM to 11PM On Point

On Point

On Point unites distinct and provocative voices with passionate discussion as it confronts the stories that are at the center of what is important in the world today. Leaving no perspective unchallenged, On Point digs past the surface and into the core of a subject, exposing each of its real world implications.

View the program guide!

Upcoming Events in your area (Submit your event today!)

Streaming audio and podcasts

Stream KOSU on your smartphone

Phone Streaming

SmartPhone listening options on this page are intended for many iPhones, Blackberries, etc. with low-cost software applications available to listen to our full-time web streams, both News on KOSU-1 and Classical on KOSU-2.

Learn more about our complete range of streaming services

We're perfecting the patient experience - Stillwater Medical Center